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Neurobiology of Disease

The Disruption of Celf6, a Gene Identified by Translational
Profiling of Serotonergic Neurons, Results in Autism-Related
Behaviors
Joseph D. Dougherty,1,2 Susan E. Maloney,1,2 David F. Wozniak,2 Michael A. Rieger,1,2 Lisa Sonnenblick,3,4,5
Giovanni Coppola,4 Nathaniel G. Mahieu,1 Juliet Zhang,6 Jinlu Cai,8 Gary J. Patti,1 Brett S. Abrahams,8
Daniel H. Geschwind,3,4,5 and Nathaniel Heintz6,7
Departments of 1Genetics and 2Psychiatry, Washington University School of Medicine, St. Louis, Missouri 63110, 3UCLA Center for Autism Research and
Treatment, Semel Institute for Neuroscience and Behavior, 4Program in Neurogenetics, Department of Neurology, and 5Department of Human Genetics,
David Geffen School of Medicine at UCLA, Los Angeles, California 90095, 6Laboratory of Molecular Biology, Howard Hughes Medical Institute, and 7The
GENSAT Project, Rockefeller University, New York, New York 10065, and 8Departments of Genetics and Neuroscience, Albert Einstein College of Medicine,
New York, New York 10461

The immense molecular diversity of neurons challenges our ability to understand the genetic and cellular etiology of neuropsychiatric
disorders. Leveraging knowledge from neurobiology may help parse the genetic complexity: identifying genes important for a circuit that
mediates a particular symptom of a disease may help identify polymorphisms that contribute to risk for the disease as a whole. The
serotonergic system has long been suspected in disorders that have symptoms of repetitive behaviors and resistance to change, including
autism. We generated a bacTRAP mouse line to permit translational profiling of serotonergic neurons. From this, we identified several
thousand serotonergic-cell expressed transcripts, of which 174 were highly enriched, including all known markers of these cells. Analysis
of common variants near the corresponding genes in the AGRE collection implicated the RNA binding protein CELF6 in autism risk.
Screening for rare variants in CELF6 identified an inherited premature stop codon in one of the probands. Subsequent disruption of Celf6
in mice resulted in animals exhibiting resistance to change and decreased ultrasonic vocalization as well as abnormal levels of serotonin
in the brain. This work provides a reproducible and accurate method to profile serotonergic neurons under a variety of conditions and
suggests a novel paradigm for gaining information on the etiology of psychiatric disorders.

Introduction
The CNS has remarkable cellular diversity with hundreds of distinct cell types based on morphology alone (Ramon y Cajal et al.,
1899). Although nearly every one of these cell types has an identical genome, each cell only uses a subset of genes as required by
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its particular functional role. Understanding this molecular genetic diversity of cell types in the CNS may provide important
insight, both for the particular roles of a given cell type as well as
for the potential consequences of genetic polymorphisms to neural circuits implicated in human disease.
We have developed techniques that permit the global assessment of translation in genetically defined cell types in vivo
(Doyle et al., 2008; Heiman et al., 2008). Here, we apply this
methodology for the first time to the serotonergic system. The
serotonergic system is thought to have important roles in regulation of basic physiological processes, such as breathing,
thermoregulation, and sleep, as well as higher cognitive phenomena, such as mood and learning. Most importantly, its
dysfunction is suspected in several neuropsychiatric diseases,
including obsessive compulsive disorder and autism, among
others (Veenstra-VanderWeele et al., 2000; Canli and Lesch,
2007; Deneris and Wyler, 2012).
Autism is a pervasive developmental disorder characterized by
core symptoms, including impairment in social interactions and
communication, as well as repetitive behaviors, restricted interests, and resistance to change (American Psychiatric Association,
2000; Fombonne, 2005). With a concordance rate reported from
60 –90% for monozygotic twins, autism clearly has a remarkably
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strong genetic component, yet, as is the case for many psychiatric
disorders, studies indicate that this genetic contribution is likely
to be complex and polygenic. In autism, those genes that have
been implicated thus far either explain only a small number of the
cases or make relatively small contributions (Moldin and
Rubenstein, 2006; Freitag, 2007; Wang et al., 2009; Weiss et al.,
2009; Abrahams and Geschwind, 2010). One possible explanation for the difficulty in discovering genes contributing to complex psychiatric disorders, such as autism, would be distinct
genetic causes in different groups of individuals. However, the
commonality of the symptoms suggests that these distinct genes
would still be impacting a common pathway or circuit in the
brain. This suggests a candidate approach, focused on particular
categories of genes, or genes expressed in particular cell types that
are a priori suspected to contribute to a particular symptom, may
increase statistical power by decreasing the number of tests.
However, one risk with candidate gene studies is that choice of
genes may be considered arbitrary or limited by our current
knowledge of relevant genes for a specific biological process.
Here, we propose that cell type specific translational profiling can
be applied to provide guidance for genetic studies of the symptomatology of CNS disorders, and we test this approach in the
case of serotonergic neurotransmission and autism.
To this end, we have applied the Translating Ribosome Affinity Purification (TRAP) methodology to identify the comprehensive in vivo suite of ribosome bound mRNA in serotonergic
neurons in adult mice. Screening the TRAP-identified serotonergic genes using human data suggested polymorphisms in the
CUGBP Elav-like family member 6 (CELF6 ) gene may contribute
to autism risk. Consistent with these findings, Celf6 mutant mice
exhibit some autism-related behaviors and abnormal brain levels
of serotonin.

Materials and Methods
Generation and husbandry of Slc6a4 TRAP mice
All protocols involving animals were approved by the Institutional Animal Care and Use Committee of Rockefeller University and the Animal
Studies Committee of Washington University. BAC transgenic mice
were generated as described previously (Gong et al., 2002), using BAC
RP24-335M24. Positive founders and subsequent eGFP-L10a-positive
progeny were bred to C57BL/6J and pups were genotyped with tail-DNA
PCR for eGFP at each generation. Lines from two independent founders
were tested for accurate expression as described below. All serotoninpositive neurons labeled with GFP in both lines. A few nonserotonergic
neurons showed trace labeling with GFP antibodies in the cingulate cortex, hypothalamus, inferior colliculi, lateral nucleus of the olfactory tract
in one of the two lines (JD57), and in the dorsal part of the caudal spinal
trigeminal nucleus in the other line (JD60, data not shown). We used line
JD60 for all subsequent experiments.

Generation and characterization of Celf6 antibodies
Peptides (QPGSDTLYNNGVSPC and AASEGRGEDRKC) from Celf6,
selected for cross-species conservation, relative uniqueness across the
Celf family, and hydrophobicity, were synthesized, conjugated to KLH,
and injected into New Zealand white rabbits following standard protocols (Green Mountain Antibodies). ELISA was used to confirm generation of antibodies specific to each peptide. High-titer rabbits were
boosted, and blood sera were affinity purified following standard protocols. Antibodies were tested for effectiveness for Western blot, and immunofluorescence, using 3T3 cells transfected with GFP-tagged and
untagged isoforms of Celf6, then fixed with 4% paraformaldehyde. Antibodies against both peptides exhibited immunoreactivity by immunoblot on protein from in Celf6 overexpressing 3T3 cells. Only antibodies
against QPGSDTLYNNGVSPC were effective for immunofluorescence
on fixed cells. Specificity was confirmed in Celf6 knock-out (Celf6 ⫺/⫺)
mouse tissue.
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Immunofluorescence and microscopy
Adult mice were killed and perfused transcardially with 15 ml PBS, then
25 ml 4% paraformaldehyde in PBS. Brains were extracted and then
cryoprotected in 30% sucrose PBS overnight, frozen in Neg 50 mounting
media (Richard Allen Scientific), and sectioned on a cryostat to 40 m of
thickness. Serial sections were collected in PBS with 0.1% sodium azide
and stored at 4°C, protected from light, until use.
EGFP-L10a expression was examined both with and without chicken
anti-GFP antibody (Abcam ab13970), and colocalization was confirmed
with rabbit anti-serotonin antibody (Immunostar), mouse anti-Neun
(Millipore Bioscience Research Reagents), detected with appropriate Alexa dye-conjugated secondary antibodies (Invitrogen). Images were captures on a LSM 510 Zeiss confocal microscope.

Immunohistochemistry
Mice were processed as above. For anti-GFP immunohistochemistry,
brains were processed by Neuroscience Associates as described previously (Doyle et al., 2008), using custom goat anti-GFP antibodies. For
Celf6 immunohistochemistry, brains were processed as above, incubated
overnight with 1:1000 with purified rabbit anti-Celf6 antibody, then
donkey anti-rabbit biotinylated secondary antibodies (Jackson ImmunoResearch Laboratories), and developed with the Vectashield Elite ABC
kit (Vector Laboratories). Sections were digitized with a Zeiss Axioskop2
and customized macros.

Translating ribosome affinity purification
Three replicate pools of five adult mice of both sexes were killed, and
brains were rapidly dissected in ice-cold dissection buffer, containing
cycloheximide, to isolate the midbrain and brainstem. TRAP was conducted as described previously (Heiman et al., 2008). Briefly, each pool
was homogenized for 12 strokes in a glass Teflon homogenizer on ice, in
buffer (10 mM HEPES [pH 7.4], 150 mM KCl, 5 mM MgCl2, 0.5 mM
dithiothreitol, 100 g/ml cycloheximide, protease inhibitors, and recombinant RNase inhibitors). Nuclei and debris were removed with centrifugation at 2000 ⫻ g for 10 min at 4°C. DHPC (Avanti) and NP-40
(Ipgal-ca630, Sigma) were added to supernatant to final concentrations
of 1% and 30 mM, respectively. After 5 min incubation of ice, supernatant
was centrifuged for 15 min at 20,000 ⫻ g, and pellet was discarded.
Supernatant was mixed with protein G-coated magnetic beads (Invitrogen), previously conjugated with a mix of two monoclonal anti-GFP
antibodies (Doyle et al., 2008), and incubated with rotation for 30 min at
4°C. Beads were washed three times with high salt wash buffer (10 mM
HEPES [pH 7.4], 350 mM KCl, 5 mM MgCl2, 1% NP-40, 0.5 mM dithiothreitol, and 100 g/ml cycloheximide), and RNA was purified from
ribosomes using Trizol (Invitrogen), following the manufacturer’s protocols, followed by DNase treatment, further purification, and concentration with RNeasy min-elute columns, following the manufacturer’s
protocol (Qiagen). RNA was also harvested in parallel from each unbound fraction of affinity purification as a measure of total tissue RNA.
RNA concentration of all samples was measured with Nanodrop spectrophotometer, and integrity was confirmed with PicoChips on the Agilent BioAnalyzer (RIN ⬎ 8).

Microarray experiments and statistical analysis
A total of 20 ng of each RNA sample was amplified with the Affymetrix
Two-Cycle amplification kit following the manufacturer’s instructions,
and quality of labeled aRNA was assessed with Bioanalyzer. Labeled RNA
from immunoprecipitated ribosomes and total tissue RNA was hybridized to separate Affymetrix Mouse Genome 430 2.0 arrays and scanned
following the manufacturer’s protocols. Data are available from the Gene
Expression Omnibus (GSE36068).
Data were analyzed using the Bioconductor module within the statistical package R. Data quality was assessed by examining raw images of
slides, boxplots, histograms, correlation coefficients, false-positive rates,
and scatterplots comparing replicate experiments. Data were normalized
as described previously (Dougherty et al., 2010) but using Affymetrix
chip definition files. Briefly, GCRMA was used to normalize within replicates and to biotinylated spike in probes between conditions. Fold
change, Specificity Index (SI), and Specificity Index statistic (pSI) were
calculated for all genes with expression above background, as described
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(Dougherty et al., 2010). Probesets with pSI ⬍ 0.01 were selected as
enriched in serotonergic neurons for the purposes of further analysis.
This resulted in 196 probesets covering 174 distinct genes.
Heirarchical clustering was conducted using Bioconductor on any
genes with pSI ⬍ 0.01 in any cell type from the current data and the initial
survey (Doyle et al., 2008).
Mouse genes from above were mapped to human Unigenes genes
using homologene, gene symbol, and BLAT of mouse mRNA against
human genome sequence, with 147 genes having clear human homologs.
Custom perl scripts were used to identify alignment coordinates of human Unigenes from UCSC genome browser, along with 10 kb of flanking
sequence to cover potential regulatory regions, with 136 Unigenes having
clear and unique genome coordinates.
Chromosomal distribution was analyzed by comparing number of
regions expected to be found on each chromosome (Wilming et al.,
2008), compared with observed number of regions.

Analysis of genome-wide association studies
The Rockefeller University Institutional Review Board and the Washington University Human Research Protection Office reviewed all human
subjects related work in this manuscript.
Deidentified human genotype and phenotype data were downloaded
with permission from the Autism Genetic Research Exchange (AGRE)
consortium (Geschwind et al., 2001) for 3787 individuals in 943 multiplex families, genotyped for 550,000 SNPs with the Illumina Hap550
platform (Wang et al., 2009). SNP genotypes were called with BeadStudio
3.1.3.0, and genotypes and phenotypes were formatted for PLINK
(Purcell et al., 2007) using Perl. Individuals with missing or poor data
were excluded (MIND ⬎ 0.1, Geno ⬎ 0.1). Only those individuals with
clearly diagnosed as autistic by AGRE were scored as affected. Those with
ambiguous diagnosis (scored NQA or broad spectrum) were excluded.
We selected all available SNPs within 10 kb of the transcription start or
end site of the serotonergic neuron enriched genes, filtered to remove
those with MAF ⬍ 0.05 and those that were out of Hardy-Weinburg
equilibrium ( p ⬍ 0.01). We further removed SNPs with an r 2 ⬎ 0.5 as
they would violate the assumption of independence for multiple testing
corrections and would not provide any further information. This resulted in a total of 555 SNPs being tested with the transmission disequilibrium test. Tests were then corrected with the Bonferroni method for
multiple testing. Tests were run for all probands (1142 trios); and because
prior work had suggested that autism in males and females may have a
separate genetic etiology (Stone et al., 2004), we further analyzed these
SNPs with males (915 trios) and females (227 trios) independently.
To determine whether segregating probands by sex was meaningful,
we performed an additional permutation analysis by randomly sampling
915 probands and repeating the analysis. Excluding SNPs in C1QTNF2
and CELF6, corrected p values ⬍0.05 were observed in only 8 of 1000
iterations, suggesting that this sex-specific difference was not spurious.

Resequencing of candidate genes
Primers were designed for resequencing following standard methods
(Montgomery et al., 2008), taking care to avoid SNPs and repetitive
sequences in locations for the primers. Standard M13F and M13R sequences were incorporated into the primers. Deidentified DNAs from
384 male white probands from distinct families within the AGRE sample
and 384 male white controls from the NIMH Human Genetic Initiative
Controls (HGIC) set were amplified with PCR.
Amplicons were then purified and Sanger sequenced using M13F or
M13R primers by Agencort Beckman Coulter Genomics. Sequences were
trimmed to exclude low-quality reads and analyzed with Seqman software to identify known and novel SNPs. Any putative novel coding sequence mutations were confirmed by sequencing with the opposite
primer.

Screening for stop mutation in additional cases and controls
An additional 864 probands from the Simons Simplex Collection (SSC)
and 4992 controls from the HGIC set were screened as follows:
HGIC samples were first screened with Sequenom. The sequence variant was run in a 29-plex SNP Genotyping Assay using Sequenom iPLEX
Gold Technology. The initial PCR, performed as per the manufacturer’s

instructions (Sequenom). The subsequent Shrimp Alkaline Phosphatase
clean, the iPLEX reaction, and the resin clean were all performed as stated
by Sequenom. Spectro chip arrays were spotted using a nanodispenser,
according to the manufacturer’s instructions. A Sequenom MALDI-TOF
spectrophotometer was used to read the array. The SpectroAquire and
MassARRAY Typer Software packages (Sequenom) were used for interpretation, and Typer analyzer Version 3.4.0.18 was used to review and
analyze all data.
Any positive HGIC samples and all SSC samples were then screened
with allele-specific PCR (Little, 2001). Primers that specifically amplify
CELF6 only with the stop codon mutation were included in a multiplex
reaction with internal control primers for ␤-actin for a final concentration of 500 nM each with Maxima SYBR Green quantitative RT-PCR
Master Mix (Fermantas), and subjected to quantitative RT-PCR in an
ABI Prism 7900, followed by a melt curve. ␤-Actin and CELF6 amplicons
were distinguished on the basis of melting temperature (83°C and 88°C,
respectively). Positive control DNA with stop codon was included on
each plate of PCR.

Analysis of 1000 genomes data
VCF files corresponding to exome sequence data from 1092 individuals
(1000 Genomes Project Consortium, 2010) were downloaded into
WASP (Dubin et al., 2010) and custom scripts used to extract all exonic
variants, annotate these with regard to likelihood of being pathogenic
(Sunyaev et al., 2001; Ng and Henikoff, 2002; Eddy, 2004; Adzhubei et al.,
2010), and then determine minor allele frequencies. The DGV was queried in March 2012 in the UCSC genome browser using the UCSC annotated CELF6 transcriptional start and stop as a query.

Quantitative real-time RT-PCR
TRAP was conducted as above for an additional three male and three
female slc6a4 bacTRAP mice. Each sample was used to synthesize cDNA
from 50 ng of total RNA using Protoscript (NEB), primed with Oligo dT,
following the manufacturer’s instructions. Quantitative RT-PCR was
conducted in a Bio-Rad IQ5 with Bio-Rad 2⫻ Sybr Green Mastermix
(Bio-Rad). Data were analyzed in the IQ5 software using the ddCT
method, with ␤-actin as a control. Melt curves were conducted to assure
specificity of product, and each product was sequenced to confirm accuracy of amplification.

Generation of Celf6 knock-out mice
Long and short arms with LoxP sites flanking exon 4 of Celf6 were cloned
by PCR adjacent to an Frt flanked neomycin-resistance cassette gene.
B6(Cg)-Tyr c-2j/j-derived ES cells were electroporated using standard
methods, and neomycin-resistant colonies were screened by PCR and
southern blot for proper integration. Positive colonies were injected into
C57BL/6J mouse blastocysts, and chimeric mice were bred to germline
Flpe expressing C57BL/6J mice to remove neomycin selection cassette,
then actin-Cre C57BL/6J mice to create germline deletions of Celf6. Recombination was confirmed in progeny by PCR. Heterozygous progeny
were crossed to generate knock-out (Celf6 ⫺/⫺) and wild-type (WT) littermate mice for behavioral and anatomical assays.

Behavioral tests
Animals and experimental design of behavioral studies. A total of 46
C57BL/6J Celf6 ⫺/⫺ (n ⫽ 23, 14 females and 9 males) and litter-matched
WT (n ⫽ 23, 14 females and 9 males) mice were used for ultrasonic pup
vocalization (USV) recording and analysis. The animal colony room
lighting was a 12:12 h light/dark cycle; room temperature (⬃20°C–22°C)
and relative humidity (50%) were controlled automatically. Standard
laboratory chow and water were available on a continuous basis.
Twenty experimentally naive male C57BL/6J Celf6 ⫺/⫺ (n ⫽ 11) and
litter-matched WT (n ⫽ 9) mice were used for adult behavioral testing.
The sequence of behavioral testing was devised to minimize “carry-over”
effects across behavioral tests as much as possible. Behavioral testing
began when the mice were 3–5 months of age and included a 1 h locomotor activity/exploration test, followed 1 d later by an evaluation on a
battery of sensorimotor measures, to assess possible disturbances in general activity and sensorimotor functions that might affect performance
on subsequent tests. One day later, the mice were tested in the Morris
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water maze, which included cued (visible platform), place (hidden platform), and probe (platform removed) trials to assess potential nonassociative deficits as well as spatial learning and memory impairments. The
following week, the mice were tested for their ability to learn another
platform location (reversal and additional probe trials) to evaluate cognitive flexibility in terms of extinguishing one learned response and acquiring another. During the next week, sociability was assessed using the
social approach test followed by an evaluation of sensorimotor reactivity
and gating by quantifying acoustic startle and prepulse inhibition (PPI).
Approximately 2–3 months later, anxiety-like behaviors were measured
in the mice by testing them in the elevated plus maze (EPM). The following week, the mice were retested on the social approach test for further
evaluation of sociability and preference for a novel conspecific (stimulus
mouse). Nineteen days later, exploratory behaviors and olfactory preference were quantified in the holeboard exploration/olfactory preference
test.
Ultrasonic vocalization recording and analysis. WT and Celf6 ⫺/⫺ pups
were individually removed from their parents at postnatal day 8 and
placed in a dark, enclosed chamber. Ultrasonic vocalizations were obtained using an Avisoft UltraSoundGate CM16 microphone, Avisoft UltraSoundGate 416H amplifier, and Avisoft Recorder software (gain ⫽ 6
dB, 16 bits, sampling rate ⫽ 250 kHz). Pups were recorded for 3 min,
after which they were weighed and returned to their home cages. Frequency sonograms were prepared from recordings in MATLAB (frequency range ⫽ 40 kHz to 120 kHz, FFT size ⫽ 256, overlap ⫽ 50%), and
individual syllables were identified and counted from the sonograms
according to a previously published method (Holy and Guo, 2005).
One hour locomotor activity and sensorimotor battery. Locomotor activity was evaluated in the mice using transparent (47.6 ⫻ 25.4 ⫻ 20.6 cm
high) polystyrene enclosures and computerized photobeam instrumentation as previously described (Wozniak et al., 2004). General activity
variables (total ambulations and vertical rearings) along with indices of
emotionality, including time spent, distance traveled, and entries made
in a 33 ⫻ 11 cm central zone and distance traveled in a 5.5 cm contiguous
peripheral zone were analyzed. All mice were also evaluated on a battery
of sensorimotor tests designed to assess balance (ledge and platform),
strength (inverted screen), coordination (pole and inclined screens), and
initiation of movement (walking initiation), as previously described
(Wozniak et al., 2004; Grady et al., 2006). For the walking initiation test,
the mouse was placed on a surface in the center of a 21 ⫻ 21 cm square
marked with tape, and the time the mouse took to leave the square was
recorded. During the balance tests, the time was recorded that the mouse
remained on a Plexiglas ledge (0.75 cm wide) or a small circular wooden
platform (3.0 cm in diameter) elevated 30 or 47 cm, respectively. The
screen tests were conducted by placing a mouse head-oriented down in
the middle of a mesh grid measuring 16 squares per 10 cm, elevated 47
cm, and angled at 60° or 90°. The time was recorded that the mouse
required to turn 180° and climb to the top. For the inverted screen, the
mouse was placed on the screen as described above; and when it appeared
to have a secure grip, the screen was inverted 180°, and the time the
mouse remained on to the screen was recorded. Each test had a maximum time of 60 s, except for the pole test, which had a maximum time of
120 s. The averaged time of two trials for each test was used for the
analyses.
Morris water navigation. Spatial learning and memory were evaluated
in the Morris water maze using a computerized tracking system (ANYmaze, Stoelting) as previously described (Wozniak et al., 2004). Cued
(visible platform, variable location) and place (submerged, hidden platform, constant location) trials were conducted, and escape path length,
latency, and swimming speeds were computed. To assess nonassociative
dysfunctions, the cued condition involved conducting 4 trials per day (60
s maximum per trial) for 2 consecutive days with the platform being
moved to a different location for each trial using a 30 min intertrial
interval, and with very few distal spatial cues being present to limit spatial
learning. Performance was analyzed across four blocks of trials (2 trials/
block). Three days later, place trials were conducted, which involved
acquisition training to assess spatial learning where mice were required to
learn the single location of a submerged platform in the presence of
several salient distal spatial cues. During the 5 consecutive days of place
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trials, the mice received 2 blocks of 2 consecutive trials [60 s maximum
for a trial; 30-s intertrial interval (spent on platform)] with each block
being separated by ⬃2 h and each mouse being released from a different
quadrant for each trial. The place trials data were analyzed over five
blocks of trials (4 trials/block) where each block represented the performance level for each of five consecutive days. A probe trial (60 s maximum) was administered ⬃1 h after the last place trial on the fifth day of
training with the platform being removed and the mouse being released
from the quadrant opposite to where the platform had been located.
Time spent in the various pool quadrants, including the target quadrant
where the platform had been placed and crossings over the exact platform location, served as the dependent variables. Three days after completing the place and probe conditions, mice were tested on reversal
trials, which involved the same procedures as the place trials, except that
the hidden platform was moved to a new location in the pool for all trials.
Another probe trial was conducted after completing the reversal trials.
Social approach. Our protocol was adapted from methods previously
described (Moy et al., 2004; Silverman et al., 2011) and involves quantifying sociability [tendency to initiate social contact with a novel conspecific (stimulus mouse) or cagemate] and preference for social novelty
(tendency to initiate social contact with a novel vs a familiar stimulus
mouse). The apparatus was a rectangular 3-chambered Plexiglas box
(each chamber measuring 19.5 cm ⫻ 39 cm ⫻ 22 cm) containing Plexiglas dividing walls with rectangular openings (5 ⫻ 8 cm) covered by
sliding Plexiglas doors. A small stainless-steel withholding cage (10 cm
h ⫻ 10 cm diameter; Galaxy Pencil/Utility Cup, Spectrum Diversified
Designs) was used to sequester a stimulus mouse. The withholding cage
consisted of vertical bars, which allowed for minimal contact between
mice but prevented fighting, and one was located in each outer chamber.
A digital video camera connected to a PC loaded with a tracking software
program (ANY-maze, Stoelting) recorded the movement of the mouse
within the apparatus and quantified time spent in each chamber and
investigation zone surrounding the withholding cages. The investigation
zones were 12 cm in diameter, encompassing 2 cm around the withholding cages. An entry into the chambers was defined when a chamber contained 80% of the mouse’s body while only the head was
tracked in the zones surrounding the withholding cages to capture
investigative social behaviors. Indirect lighting illuminated the test
room, and the entire apparatus was cleaned with Nolvasan solution
while the withholding cages were cleaned with 75% ethanol solution
between tests.
The first test sequence consisted of 3 consecutive 10 min trials. For the
first trial, each mouse was placed in the middle chamber with the doors to
the outer chambers shut to become acclimated to the apparatus. During
the second trial, the mouse was allowed to freely investigate and habituate
to all three chambers, including the empty withholding cages (Page et al.,
2009; Naert et al., 2011; Pobbe et al., 2012). Neither group showed prior
preference for a particular withholding cage during habituation. The
third (test) trial assessed sociability exhibited toward a novel stimulus
mouse versus a familiar, empty withholding cage by placing an unfamiliar, gender-matched stimulus mouse in one withholding cage while the
other was left empty, and the test mouse was allowed to freely explore the
apparatus and investigate the novel mouse in the withholding cage. A
second test sequence conducted ⬃2 months later also consisted of 3
consecutive 10 min trials. For trial 1, each mouse was allowed to freely
investigate and habituate to all three chambers, including the empty
withholding cages. For the second trial, a gender-matched cagemate was
placed in one withholding cage while the other remained empty, and the
test mouse could freely explore the apparatus and investigate the cagemate in the withholding cage. During the third (test) trial, the familiar
cagemate remained in the withholding cage, although a new, unfamiliar
gender-matched stimulus mouse was now placed in the other withholding cage, and the test mouse was allowed to explore the apparatus and
investigate the two mice contained in the withholding cages. The locations of the stimuli mice in the outer chambers for the first test sequence
were counterbalanced within and across groups, and placement of the
stimuli mice for the second test sequence was randomized. All stimuli
mice were acclimated to the metal withholding cages for 10 min before
beginning of testing.
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Acoustic startle/prepulse inhibition. Sensorimotor reactivity and gating
were also evaluated in the mice by quantifying their acoustic startle response (ASR) and PPI because PPI has been reported to be abnormal in
individuals with autism (Perry et al., 2007; Yuhas et al., 2011). The ASR
and PPI were tested using computerized instrumentation designed specifically for mice (StartleMonitor, Kinder Scientific). The ASR to a 120
dBA auditory stimulus pulse (40 ms broadband burst) and PPI (response
to a prepulse plus the startle pulse) were measured concurrently using
our previously described methods (Hartman et al., 2001; GallitanoMendel et al., 2008). Beginning at stimulus onset, 65, 1 ms force readings
were averaged to obtain an animal’s startle amplitude for a given trial. A
total of 20 startle trials were presented over a 20 min test period, during
which the first 5 min served as an acclimation period when no stimuli
above the 65 dB white noise background were presented. The session
began and ended by presenting 5 consecutive startle (120 db pulse alone)
trials unaccompanied by other trial types. The middle 10 startle trials
were interspersed with PPI trials, consisting of an additional 30 presentations of 120 dB startle stimuli preceded by prepulse stimuli of 4, 12, or
20 dB above background (10 trials for each PPI trial type). A percent PPI
score for each trial was calculated using the following equation: %PPI ⫽
100 ⫻ (ASRstartle pulse alone ⫺ ASRprepulse ⫹ startle pulse)/ASRstartle pulse alone
(see Hartman et al., 2001 for more details).
EPM. Anxiety-like behaviors were evaluated in the EPM according to
our previously described procedures (Schaefer et al., 2000; Boyle et al.,
2006). Our apparatus consisted of two opposing open arms and two
opposing enclosed arms (36 ⫻ 6.1 ⫻ 15 cm) that extended from a central
platform (5.5 ⫻ 5.5 cm), which were constructed of black Plexiglas. The
maze was equipped with pairs of photocells configured in a 16 (x-axis) ⫻
16 ( y-axis) matrix, the output of which was recorded by a computer and
interface assembly (Kinder Scientific). A system software program (MotorMonitor, Kinder Scientific) enabled the beam-break data to be recorded and analyzed to quantify time spent, distance traveled, and entries
made into the open and closed arms and center area. To adjust for differences in general activity, the percentage of distance traveled, time
spent, and entries made into the open arms out of the totals (open
arms ⫹ closed arms) for each variable were also computed. Test sessions
were conducted in a dimly lit room where light was provided by two 13 W
black-light bulbs (Feit EcoBulbs) and each session began by placing a
mouse in the center of the maze and allowing it to freely explore the
apparatus. Each test session lasted 5 min, and the mice were tested over 3
consecutive days.
Holeboard exploration/olfactory preference test. Mice were evaluated for
possible differences in exploratory behaviors and olfactory preferences
using a slightly modified version of our previously published methods
(Ghoshal et al., 2012) where hole poking served as the main behavioral
response. Our modifications were based on procedures described by
Moy et al. (2008) for Study 2 within their publication to assess shifts in
olfactory preference in an autism mouse model. We used the same odorant, familiarization technique, and testing procedure, although our apparatus is slightly different from the one used by these authors. Our
protocol involved the use of a computerized holeboard apparatus (41 ⫻
41 ⫻ 38.5 cm high clear plastic chamber), containing 4 corner and 4 side
holes in the floor, with a side hole being equidistant between the corner
holes (Learning Holeboard; MotorMonitor, Kinder Scientific). Pairs of
photocells were contained within each hole (27 mm in diameter) and
were used to quantify the frequency and duration of pokes, whereby a
poke that was at least 35 mm in depth was required to be registered as a
hole-poke. Each mouse received one 30 min habituation session in the
holeboard during which no holes contained any odorants. The following
day (test session 1), a 20 min session was conducted during which holepoke frequency and duration data were collected in the presence of
empty and odorant-containing holes. All side holes were empty, while
odorants were placed at the bottom of each of three corner holes, although access to the odorants was blocked, and one corner hole remained empty. The configuration of odorant-containing and empty
corner holes (see Fig. 7C) was such that one hole contained a familiar
odorant (fresh corn-cob bedding used in the home cages), which was
placed in a corner hole opposite to a corner hole containing an unfamiliar
odorant (woodchip bedding). Another novel odorant (chocolate chips)

was placed in a corner hole opposite to the empty corner hole. This
pattern was counterbalanced within and across groups. Immediately after completing test session 1, the mice were familiarized with the chocolate chips by placing 4 –7 chocolate chips in each home cage. The same
thing was done on the following day, and all but 1 chocolate chip were
consumed before the start of the second test session. Test session 2 was
conducted two days after test session 1 using the same procedures and
pattern of odorant-containing and empty corner holes, except that the
actual configuration used for test session 2 was opposite to the one used
during test session 1 (see Fig. 8C). For example, the corner holes that
contained bedding for test session 1 contained chocolate chips or were
empty during test session 2, and vice versa. General exploratory behavior
was evaluated by quantifying total hole-pokes as well as pokes into the
side and corner holes for test sessions 1 and 2. Olfactory preferences were
assessed by analyzing poke frequencies involving odorant-containing
and empty corner holes within and between groups. Poke durations
exhibited for the different types of holes were also analyzed to provide
additional data on possible differences in the processing of olfactory
stimuli.
Statistical analyses for behavioral data. ANOVA models were used to
analyze the behavioral data. A two-way ANOVA model was used to analyze differences within and between genotype and sex for USV. Repeated measures (rm) ANOVA models containing one between-subjects
variable (genotype) and one within-subjects (repeated measures) variable (e.g., blocks of trials) were typically used to analyze the learning and
memory data. The Huynh-Feldt adjustment of ␣ levels was used for all
within-subjects effects containing more than two levels to protect against
violations of sphericity/compound symmetry assumptions underlying
rmANOVA models. Typically, one-way ANOVA models were used to
analyze differences between groups for 1 h locomotor activity test and
measures in the sensorimotor battery. Planned comparisons were conducted within ANOVA models for certain holeboard variables. In most
other instances, pairwise comparisons were conducted following relevant, significant overall ANOVA effects, which were subjected to Bonferroni correction when appropriate.

Extraction for measurement of neurotransmitter levels

Ten Celf6 ⫺/⫺ and seven WT whole adult mouse brains frozen at ⫺80°C
were dried on a lyophilizer for 72 h. The dried brains were crushed to a
powder and stored at ⫺80°C. A total of 10 mg of each was extracted as
follows: vortexed 30 s; centrifuged 13,000 RPM, 4°C, 10 min; sonicated at
50°C in a bath sonicator; stored at ⫺4°C; liquid nitrogen bath 1 min and
then allowed to thaw. Acetone (600 l at 4°C) was added to each tube.
Tubes were vortexed, placed in liquid nitrogen and sonicated for 10 min;
this was repeated three times. Samples were incubated for 30 min
and then centrifuged. Supernatant was poured into new microcentrifuge
tubes and stored. Methanol, water, and formic acid (400 l at 86.5:
12.5:1) were added to the remaining pellet. Tubes were vortexed, sonicated for 15 min, and incubated for 30 min. Samples were centrifuged,
and the supernatant was combined with the previous 600 l. The pooled
supernatant was dried with a speedvac with no heat for 23 h. To each
tube, 100 l of water was added. Tubes were sonicated for 5 min and
incubated for 1 h. Samples were centrifuged and the resulting supernatant
was transferred to deactivated glass autosampler vials for MS analysis.

LC/MS analysis
Targeted LC/MS analyses were done using an HPLC system (Agilent
1260 Infinity) coupled to an Agilent 6460 Triple Quadrapole MS operated in positive ESI mode. Analytes were separated using a Zorbax 300
SB-C18 (5 m, 150 ⫻ 0.5 mm) column. An isocratic elution was used
with 0.1% v/v formic acid in water. The injection volume was 0.8 l. A 30
min wash was performed between injections. Flow was set to 5 l/min.
Source conditions were gas temperature 300°C, gas flow 6 L/min, nebulizer 15 psi, capillary 4000 V. Acquisition settings were dwell time 200 ms,
MS1 resolution unit, MS2 resolution unit, polarity positive, cell accelerator voltage 7. The 6460 Triple Quadrapole was operated in MRM mode
monitoring two transitions for each analyte with the most intense transition being used for analysis. MRM transitions were integrated with
Agilent Mass Hunter Qualitative Analysis B.04.00. Statistical analysis was
conducted in MS Excel using 2-tailed t tests, with Bonferroni correction.
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Results
Slc6a4 bacTRAP mice target eGFP-L10a specifically to
serotonergic neurons
Classical studies using a variety of methodologies (Hillarp et al.,
1966; Steinbusch, 1981, 1984; Ishimura et al., 1988), including in
situ hybridization studies of the presynaptic serotonin transporter Slc6a4 (Bengel et al., 1997), have defined nine populations
of serotonergic neurons, predominantly within the raphe nuclei.
To enable translational profiling of these cells, we generated
transgenic mouse lines using a Slc6a4 BAC to drive the expression
of the TRAP construct (eGFP fused to the ribosomal protein
L10a). Immunohistochemistry with anti-GFP antibodies demonstrated robust expression in a pattern consistent with expression in all serotonergic neurons (Fig. 1A, B). Neurotransmitter
phenotype was confirmed using confocal immunofluorescence
with antibodies to GFP and serotonin (Fig. 1C). In all cells, GFP
signal was seen only in the cytoplasm and nucleolus, consistent
with ribosomal incorporation of the fusion protein.
Serotonergic neurons have a distinct translational profile
Using eGFP as an affinity tag, we purified the suite of ribosome
bound mRNAs from serotonergic neurons (the TRAP methodology) (Doyle et al., 2008, Heiman et al., 2008) and interrogated
them with microarrays. Independent biological replicates
showed high reproducibility (Fig. 2A), with an average correlation ⬎0.99. When these samples were compared with microarrays of the whole tissue (Fig. 2B), there was a clear, robust, and
comprehensive enrichment of all mRNAs known to be specifically expressed in serotonergic neurons, including enzymes in the
pathway for synthesizing serotonin in the CNS (Tph2, Ddc)
(Goridis and Rohrer, 2002), transcription factors known to be
important for specifying these neurons (Goridis and Rohrer,
2002; Pfaar et al., 2002) (Fev, Gata2, and Gata3), the serotonin
autoreceptor (Htr1a; Korte et al., 1996), and the serotonin transporter itself (Slc6a4 ). There was also a clear depletion of mRNAs
known to not be expressed by neurons, such as the glial genes
Mobp, Aldh1L1, Mbp, and Plp. This suggests that we could indeed
capture mRNA specifically from serotonergic neurons.
To select for all mRNAs used in serotonergic neurons, we
removed those probesets with median expression ⬍50, or a fold
change below a background threshold determined by the glial
genes (Dougherty et al., 2010). These normalized data represent
⬎5000 genes clearly expressed in serotonergic neurons.
To generate a comprehensive list of those mRNAs either
highly enriched or specific for serotonergic neurons, we compared this translational profile to our previous survey of cell types
in the CNS (Doyle et al., 2008) using the pSI statistic (Dougherty
et al., 2010). We identified 196 probesets with pSI ⬍ 0.01 (Table
1), corresponding to 174 genes that included the known serotonergic cell genes listed above. To validate this list, we compared it
to the online catalog of mouse in situ hybridizations of the
Allen Brain Atlas (Lein et al., 2007) in a blinded and unbiased
manner (Dougherty et al., 2010). Compared with a random
list of genes from the array, the serotonergic cell list had nearly
three times as many in situ hybridizations with a pattern of
enrichment in the raphe nuclei. Seventeen of these genes
scored as specific to serotonergic neurons, compared with
none from the random list (Fig. 2C).
We next compared our list of enriched and specific genes with
the recently published data from flow-sorted embryonic serotonergic neurons from rostral and caudal nuclei (Wylie et al., 2010).
There are numerous differences in methodology and design between the two studies, including age (embryonic vs adult), puri-
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fication methodology (flow sorting vs TRAP), amplification
methodology, normalization, and analytical strategy. Despite
this, there was highly significant overlap between the two studies
( 2 test, p ⬍ 8.7E ⫺227), suggesting good conservation of gene
expression across development for these neurons. Thus, the lines
generated here provide in vivo access to the translational profile
of the adult serotonergic system and can be used in the future to
study the response of these cells to whole animal manipulations
in a reproducible and accurate manner.
Using hierarchical clustering, we compared the serotonergic
translational profile to the cell types from our previous survey
(Doyle et al., 2008; Fig. 2D). Serotonergic neurons are clearly
distinct from other cells. However, remarkably, of the surveyed
cell types, serotonergic neurons are most similar to cholinergic
neurons of the basal forebrain. Although these two populations
come from distinct regions and have distinct transmitter phenotypes, both have similar functional roles; that is, both cell types
project widely through the CNS and function as neuromodulators, influencing the physiological properties of whole circuits.
This suggests that the translational profile of a cell population is
more strongly influenced by its particular roles within the CNS
than the region in which it is found or the particular neurotransmitter it uses.
Next, we performed a standard Gene Ontologies analysis
on the 174 serotonergic genes using DAVID (Dennis et al.,
2003), which indicated, unsurprisingly, a role for a significant
fraction of these genes in serotonin signaling (not shown).
However, many other genes were unannotated, and we suspected that these 174 genes may provide a novel list of candidate genes for neuropsychiatric disorders thought to involve
the serotonergic system.
Of the 174, 147 had clear human homologues based on homologene, BLAT, and probematchDB (Wang et al., 2002). These
were distributed across 136 noncontiguous regions of the genome. Chromosomal analysis revealed a remarkably nonrandom
distribution of these regions ( 2 test, p ⬍ 3.57E ⫺7). In particular,
10.4% of these were found on the X chromosome, compared with
the 4.5% that would be expected to be found there by chance
given the size and gene density of the chromosomes. This is interesting considering the gender disparity in prevalence for autism (4:1 male to female; Fombonne, 2005) and depression (1: 1.7
male to female; Kessler et al., 1993), two of the disorders with
suspected connections to the serotonergic system.
Transmission disequilibrium testing for polymorphisms in
serotonergic genes in autism
We next sought to determine whether polymorphism in these
136 regions may be related to autism, using the Transmission
Disequilibrium Test (Spielman and Ewens, 1996; Collins, 2007),
applied to data generated by AGRE (Geschwind et al., 2001;
Wang et al., 2009) from multiplex families with autism. We discovered two SNPs that met criteria for significance after multiple
testing correction (Table 2): one in both males and females in the
C1QTNF2 gene and one specifically in males in the gene encoding
the CELF6 RNA-binding protein.
We decided to first focus on the CELF6 gene because another
RNA-binding protein, FMRP, is disrupted in fragile X syndrome,
the most common syndromic cause of autism (Verkerk et al.,
1991; Chonchaiya et al., 2009). CELF6 is a less well-studied member of an RNA binding protein family known as the CELF family
(Cugbp and Etr-3 like factors) (Barreau et al., 2006). CELF proteins are known to regulate RNA in a variety of manners. In
Drosophila, this family has been studied in the context of regula-
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Figure 1. A bacTRAP line for serotonergic neurons. A, DAB immunohistochemistry with anti-GFP antibodies on Slc6a4 bacTRAP mice reveals eGFP-L10a transgene expression in the known
serotonin cell-containing nuclei. B, Higher magnification of DRV shows neuronal morphology of eGFP-positive cells. C, Confocal immunofluorescence colocalization of eGFP-L10a transgene with
neurotransmitter serotonin. Abbreviations following Paxinos (Franklin and Paxinos, 1997). Coordinates relative to interaural. IPN, Interpeduncular nucleus; ml, medial lemniscus; RMg, raphe
magnus; ROb, raphe obscurus; RPa, raphe pallidus; LPGi, lateral paragigantocellular nucleus; DRD, dorsal raphe dorsal; DRI, dorsal raphe interfasicular; DRL, dorsal raphe lateral; DRV, dorsal raphe
ventral; PDR, posterodorsal raphe; MnR, median raphe; CLi, caudal linear raphe.

tion of translation (Good et al., 2000); whereas in Xenopus, homologous proteins are implicated in mRNA localization and
stability (Barreau et al., 2006). In mammals, family members are
known to both positively and negatively regulate splicing of a

variety of transcripts (Ladd et al., 2004), and members of the
CELF family seem to be in a dynamic competition with other
splicing factors to regulate cell type-specific alternative splicing
(Charlet et al., 2002).
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Figure 2. Reproducible and accurate polysome purification from serotonergic neurons. A, Scatterplot of probeset signal intensity (log10) for independent biological replicate TRAP experiments
reveals extremely high reproducibility. Black lines indicate fold change ⫽ 0.5 and 2. B, Scatterplot of mRNA TRAPed from serotonergic neurons (average of 3 replicates, x-axis), compared with mRNA
from hindbrain (average of 3 replicates, y-axis), reveals a robust enrichment for genes expressed in serotonergic neurons (blue), but not for known glial genes (red). C, Blinded analysis of in situ
hybridization patterns for probesets predicted to be enriched in serotonergic neurons (light gray, n ⫽ 197), compared with randomly selected probesets (dark gray, n ⫽ 197), reveals a robust
overrepresentation of raphe-specific and enriched genes in serotonergic neuron gene list ( p ⬍ 1E ⫺66,  2 test). D, Hierarchical clustering of TRAP data for serotonergic neurons with previously
characterized cell types (Doyle et al., 2008).

SNP rs2959930 is found near an alternative transcriptional
start site of CELF6
The CELF6 gene has 16 exons (Fig. 3A) and is highly homologous
to other CELF genes, particularly CELF3 (TNRC4), CELF4, and
CELF5. Their long isoforms each contain three RNA recognition
motifs (RRMs) that are nearly identical across family members,
and a divergent domain, required in other family members for
both splicing activity and repression (Han and Cooper, 2005). In
other family members, the first two RRMs are required for RNA
binding (Good et al., 2000), whereas the third may be involved in
nuclear localization (Chapple et al., 2007).
The SNP associated with autism in the AGRE male probands,
rs2959930, is found in the 5⬘ UTR of an alternative first exon (Fig.
3C). Inclusion of this exon precludes the incorporation of the
first RRM (Fig. 3D). In family member CELF2, truncations removing the first RRM reduce the inclusion of GRIN1 exon 21 in
a minigene splicing assay (Han and Cooper, 2005). This would

suggest that polymorphisms that impact the transcription, translation, or stability of the different isoforms of CELF6 may have an
impact on the splicing, localization, and translation of mRNA
within the cell. However, it is unclear whether SNP rs2959930 is a
relevant functional polymorphism or whether it is in linkage disequilibrium with a more profound variation. First, we sought to
determine whether both isoforms are expressed in serotonergic
neurons and to confirm that CELF6 is indeed being translated in
these cells. Then, we initiated a screen for more profound polymorphisms that may be influencing this gene in autism.
Celf6 is found in serotonergic neurons
To determine which isoforms might be used in serotonergic neurons, we designed primers specific to the long and short isoforms.
Quantitative RT-PCR clearly confirmed an enrichment of Celf6
mRNA in serotonergic neurons (data not shown), with both isoforms detectable. To investigate whether Celf6 protein is also
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Table 1. Serotonin cell-specific and enriched genes
Gene symbol

Probe set ID

pSI

Name

Acsl4
Ankrd2
Apoa2
Arhgdig
Asb4
Celf6
C1qtnf2
Calcr
Calr3
Cckar
Cd1d1
Ceacam10
Cep63
Chodl
Ciapin1
Cited1
Col7a1
Cpa3
Cpne8
Cryba2
Cthrc1
Ctla2b
Cxcl7
Ddc
Dlk1
Dnajc12
E2f5
En1
Esm1
Fbxw4
Fev
Fgd5
Foxa1
Fxyd5
Fxyd6
Gas5
Gata2
Gata3
Gch
Glra2
Gm1574
Gnas
Gng2
Gnpda2
Gpr1
Gpr4
Gpx3
Gstm6
Guca1a
Gus
H2-Q1
Hcrtr1
Hoxb3
Hs6st2
Htr1a
Htr1d
Htr5b
Igh-6
Igh-VJ558
Il1r1
Ing1
Irs4
Klk27
Krt2–1

1451828_a_at
1419621_at
1417950_a_at
1448660_at
1433919_at
1429790_at
1431079_at
1418688_at
1453232_at
1421195_at
1449131_s_at, 1449130_at
1448573_a_at, 1417074_at
1436274_at
1451440_at
1438163 xat
1449031_at
1419613_at
1448730_at
1430521_s_at, 1430520_at
1419011_at
1452968_at
1416811_s_at, 1448471_a_at
1418480_at
1430591_at, 1426215_at
1449939_s_at
1417441_at
1434493_at
1418618_at
1449280_at
1442674_at
1425886_at
1460578_at
1418496_at
1418296_at
1417343_at
1449410_a_at
1428816_a_at, 1450333_a_at
1448886_at
1429692_s_at, 1420499_at
1434098_at
1446591_at
1421740_at
1418451_at
1457230_at
1460123_at
1457745_at
1449106_at
1422072_a_at
1421061_at
1430332_a_at
1418734_at
1436295_at
1456229_at
1420938_at, 1450047_at
1438710_at
1440166_x_at, 1440741_at
1422196_at
1427351_s_at, 1427329_a_at
1425763_x_at, 1421653_a_at
1448950_at
1456857_at
1441429_at
1421587_at
1422481_at

6.54E-04
1.72E-03
9.57E-03
4.87E-04
1.91E-06
8.40E-03
8.01E-03
1.91E-06
2.20E-03
1.43E-03
1.91E-06
1.91E-06
1.91E-06
3.57E-03
1.97E-03
1.91E-06
1.91E-06
1.91E-06
2.19 to 3.24E-03
1.91E-06
5.54E-05
1.91E-06
1.91E-06
1.91E-06
1.91E-06
3.44E-05
4.57E-04
1.34E-05
2.87E-05
7.26E-03
1.91E-06
1.91E-06
7.42E-03
1.91E-06
9.95E-03
2.42E-04
1.91E-06
1.91E-06
1.91E-06
2.58E-04
1.91E-06
6.19E-04
6.11E-03
3.19E-04
5.89E-04
1.91E-06
1.34E-05
1.83E-04
1.91E-06
3.05E-03
1.91E-06
1.91E-06
4.80E-03
2.05E-04 to 1.91E-06
1.91E-06
4.22E-04 to 1.91E-06
1.91E-06
5.75E-03 to 1.91E-06
3.82 to 1.91E-06
7.70E-04
2.10E-05
1.91E-06
1.91E-06
6.65E-03

Acyl-CoA synthetase long-chain family member 4
Ankyrin repeat domain 2 (stretch responsive muscle)
Apolipoprotein A-II
Rho GDP dissociation inhibitor (GDI) gamma
Ankyrin repeat and SOCS box-containing protein 4
Cugbp and Elav-like family member 6, RNA binding protein
C1q and tumor necrosis factor related protein 2
Calcitonin receptor
Calreticulin 3
Cholecystokinin A receptor
CD1d1 antigen
CEA-related cell adhesion molecule 10
Similar to protein C6orf117
Chondrolectin
Rhomboid domain containing 2
Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 1
Procollagen, type VII, alpha 1
Carboxypeptidase A3, mast cell
Copine VIII
Crystallin, ␤ A2
Collagen triple helix repeat containing 1
cytotoxic T lymphocyte-associated protein 2 ␤
Chemokine (C-X-C motif) ligand 7
Dopa decarboxylase
Delta-like 1 homolog (Drosophila)
DnaJ (Hsp40) homolog, subfamily C, member 12
E2F transcription factor 5, p130-binding
Engrailed 1
Endothelial cell-specific molecule 1
F-box and WD-40 domain protein 4
FEV (ETS oncogene family)
FYVE, RhoGEF. and PH domain containing 5
Forkhead box A1
FXYD domain-containing ion transport regulator 5
FXYD domain-containing ion transport regulator 6
Growth arrest-specific 5 (non-protein coding)
GATA binding protein 2
GATA binding protein 3
GTP cyclohydrolase 1
Glycine receptor, ␣ 2 subunit
Gene model 1574, (NCBI)
GNAS (guanine nucleotide binding protein, ␣ stimulating) complex locus
Guanine nucleotide binding protein (G protein), ␥ 2 subunit
Glucosamine-6-phosphate deaminase 2
G protein-coupled receptor 1
G protein-coupled receptor 4
Glutathione peroxidase 3
Glutathione S-transferase,  1
Guanylate cyclase activator 1a (retina)
Glucuronidase, ␤
histocompatibility 2, Q region locus 1
Hypocretin (orexin) receptor 1
Homeo box B3
Heparan sulfate 6-O-sulfotransferase 2
5-Hydroxytryptamine (serotonin) receptor 1A
5-Hydroxytryptamine (serotonin) receptor 1D
5-Hydroxytryptamine (serotonin) receptor 5B
Immunoglobulin heavy chain 6 (heavy chain of IgM)
Immunoglobulin heavy chain (J558 family)
Interleukin 1 receptor, type I
Inhibitor of growth family, member 1
Insulin receptor substrate 4
Kallikrein 1-related peptidase b27
Keratin complex 2, basic, gene 1
(Table continues.)
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Table 1. Continued
Gene symbol

Probe set ID

pSI

Name

Lgals8
Lst1
Maob
Mbd1
Mcpt5
Nanos1
Nkx6-1
Nos3
Nrl
Oas1e
Pcbd
Pcdha4
Pcdha6
Pcdhac1
Pcsk1
Pcsk5
Pdzk8
Prph1
Ptger3
Resp18
Rims3
Rpgrip1
Rph3al
Rpl37a
Rps27
Saa1
Scg2
Scn9a
Siat8f
Slc18a2
Slc22a3
Slc6a4
Sln
Sncg
Stard3 nl
Stk32b
Swam2
Tinag
Tmie
Tnfrsf11b
Tph2
Trh
Trpm4
Twsg1
Zar1
Zfp622
Zwint

1422661_at
1425548_a_at
1434354_at
1430838_x_at, 1453678_at
1449456_a_at
1436648_at
1425828_at
1434092_at
1450946_at
1416847_s_at
1418713_at
1424341_s_at
1451769_s_at
1425017_at
1421396_at
1451406_a_at, 1437339_s_at
1439088_at
1422530_at
1450344_a_at
1417988_at
1459042_at
1454231_a_at
1444409_at
1416217_a_at
1460699_at
1419075_s_at
1450708_at
1442333_a_at, 1442810_x_at, 1442809_at
1456147_at, 1456440_s_at
1437079_at
1420444_at
1417150_at
1420884_at
1417788_at
1430274_a_at
1431236_at
1449191_at
1419314_at
1441926_x_at, 1443964_at
1449033_at
1435314_at
1418756_at
1435549_at
1441302_at
1434494_at
1447775_x_at
1444717_at

4.22E-03
1.92E-03
1.91E-06
4.20E-03 to 7.45E-05
7.07E-05
8.47E-03
1.10E-03
8.57E-03
1.91E-06
1.91E-06
1.09E-04
3.91E-03
7.28E-03
1.91E-06
1.91E-06
2.89E-03 to 6.66E-03
1.91E-06
3.16E-03
1.91E-06
2.03E-04
1.75E-03
1.91E-06
2.10E-05
9.57E-03
2.10E-05
1.51E-04
3.12E-04
1.91E-06
9.94E-05 to 1.91E-06
1.91E-06
1.91E-06
1.91E-06
3.20E-03
1.91E-06
7.55E-03
1.91E-06
1.91E-06
1.91E-06
1.26E-03 to 5.76E-03
4.80E-03
1.91E-06
1.91E-06
5.66E-03
8.37E-03
2.10E-05
8.60E-04
7.90E-03

Lectin, galactose binding, soluble 8
Leukocyte specific transcript 1
Monoamine oxidase B
Methyl-CpG binding domain protein 1
Chymase 1, mast cell
Nanos homolog 1 (Drosophila)
NK6 transcription factor related, locus 1 (Drosophila)
Nitric oxide synthase 3 antisense
Neural retina leucine zipper gene
2⬘-5⬘ Oligoadenylate synthetase 1E
Pterin 4 ␣ carbinolamine dehydratase
Protocadherin ␣ 4
Protocadherin ␣ 6
Protocadherin ␣ subfamily C, 1
Proprotein convertase subtilisin/kexin type 1
Proprotein convertase subtilisin/kexin type 5
PDZ domain containing 8
Peripherin 1
Prostaglandin E receptor 3 (subtype EP3)
Regulated endocrine-specific protein 18
Regulating synaptic membrane exocytosis 3
Retinitis pigmentosa GTPase regulator interacting protein 1
Rabphilin 3A-like (without C2 domains)
Ribosomal protein L37a
Ribosomal protein S27
Serum amyloid A1
Secretogranin II
Sodium channel, voltage-gated, type IX, ␣
ST8 ␣-N-acetyl-neuraminide ␣-2,8-sialyltransferase 6
Solute carrier family 18 (vesicular monoamine), member 2
Solute carrier family 22 (organic cation transporter), member 3
Solute carrier family 6 (neurotransmitter transporter, serotonin), member 4
Sarcolipin
Synuclein, ␥
STARD3 N-terminal like
Serine/threonine kinase 32B
WAP four-disulfide core domain 12
Tubulointerstitial nephritis antigen
Transmembrane inner ear
Tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin)
Tryptophan hydroxylase 2
Thyrotropin releasing hormone
Transient receptor potential cation channel, subfamily M, member 4
Twisted gastrulation homolog 1 (Drosophila)
Zygote arrest 1
Zinc finger protein 622
ZW10 interactor

Probesets corresponding to all named genes with pSI ⬍ 0.01 are listed.

found in serotonergic neurons, we generated antibodies to Celf6.
Quantitative RT-PCR of 3T3 cells suggested no endogenous expression of Celf6. Experiments with these cells transiently expressing long or short isoforms, or a GFP fusion, demonstrate
that these antibodies can detect Celf6 by SDS-PAGE (Fig. 4A) or
in fixed cells (Fig. 4B).
Immunofluorescence in Slc6a4 bacTRAP mice reveals colocalization of eGFP with Celf6 immunoreactivity in raphe neurons
(Fig. 4C). Celf6 immunoreactivity is also seen in a few other
neuromodulatory populations, including the noradrenergic locus ceruleus, populations of cells in the hypothalamus, including
presumptive dopaminergic cells of the arcuate nucleus, and a few,
scattered, dimly labeled cells in cortex (data not shown). Unlike
other presumptive neuronal splicing factors, which are predominantly nuclear (Underwood et al., 2005), labeling is largely cyto-

plasmic, suggesting that in the brain Celf6 may have roles beyond
splicing. Having confirmed Celf6 protein is found in serotonergic
neurons, we next conducted a screen to identify additional variants that may be associated with human autism.
Resequencing of candidate exons in CELF6 identifies rare
premature stop codon
Toward an understanding of the extent to which CELF6 tolerates
genetic variation in humans, we used publicly available exome
data from 1092 individuals, to compare SNV rates here with
those in all other RefSeq protein coding genes (n ⫽ 19,032).
Although tolerance for nonsynonymous variation was seen to
vary, the large majority of annotated genes (n ⫽ 14,022) were
observed to harbor one or more SNVs predicted to be deleterious
(2⫹ of BLOSUM62, Polyphen2, and SIFT) (Sunyaev et al., 2001;
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Table 2. Transmission disequilibrium in SNPs near two serotonergic neuron genes in human autistic probands

Chromosome
Male probands
15
5
14
5
8
Female probands
17
16
23
5
4
Male and female probands
5
14
15
8
10

SNP

A1
(minor allele)

A2
(major allele 2)

No. of observations of minor
allele transmission to
individual with autism

No. of observations
of untransmitted
minor allele

OR

rs2959930
rs9313845
rs8003220
rs17409286
rs11573856

G
A
A
A
A

A
G
G
G
G

273
110
38
144
113

378
171
77
203
165

rs4470197
rs9929530
rs4599945
rs3762986
rs11731545

G
C
A
A
A

A
A
C
G
G

70
52
6
93
90

rs9313845
rs8003220
rs2959930
rs11573856
rs363341

A
A
G
A
A

G
G
A
G
G

129
48
352
143
400

p value

Bonferonnicorrected
p value

Gene

0.72
0.64
0.49
0.71
0.68

3.87E-05
0.000274
0.000276
0.001539
0.001816

0.02521
0.1785
0.18
1
1

CELF6
C1QTNF2
IGH
C1QTNF2
TNFRSF11B

113
88
22
138
56

0.62
0.59
0.27
0.67
1.61

0.00148
0.002346
0.002497
0.003069
0.004895

0.9647
1
1
1
1

CCDC55
TMEM114
DGKK
PCSK1
TNFRSF11B

202
92
451
205
498

0.64
0.52
0.78
0.70
0.80

6.01E-05
0.0002
0.000477
0.000889
0.001074

0.03918
0.1306
0.3107
0.5795
0.7005

C1QTNF2
IGH
CELF6
TNFRSF11B
SLC18A2

A
RRM1

RRM3
RRM2

a
b
c
d
e
14

B

13

12............5

4

chr15: 72,580,000

3

72,581,000

C

72,582,000

RRM3

1b

chr15:

2

1a

72,597,500 72,598,000 72,598,500 72,599,000 72,599,500

RRM1

RRM2
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B2
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B1
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UCSC Genes
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Mus BC057083
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Mus AK018246
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d
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CELF6
CELF6

Mammal
Vertebrate

200
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Figure 3. CELF6 gene, exons, domains, and regions of interest. A, UCSC genome browser view of the CELF6 gene in human, showing 16 exons (blue numbers), 5 putative isoforms (a– e), and
alignment of the 3 RRMs. B, First candidate region, covered by two amplicons (B1 and B2), encompassing short poly-glutamine sequence (polyQ) and putative human-specific exon (red arrow).
Human CELF6 exons are shown condensed in blue, and aligned mouse mRNAs are shown below in black. C, Second candidate region, covered by two amplicons (A3 and A4), encompassing the
alternative first exon, and highly conserved putative promotor region (purple, brown) and the associated SNP RS2959930. D, Illustration of CELF6 protein isoforms. Isoform “a” of CELF6, which
includes the alternative first exon (1b), does not contain the first RRM.

Ng and Henikoff, 2002; Eddy, 2004; Adzhubei et al., 2010) and
present at an appreciable frequency in this population (⬎1%).
Consistent with intolerance to nonsynonymous variation, no
such events were observed within CELF6. Similarly, no structural
variants overlapping with CELF6 were observed in the DGV

(Iafrate et al., 2004). Although power issues currently limit a
precise ranking of how tolerant different genes are to genetic
variation, consideration of all coding variation put CELF6 at the
97th percentile of all annotated genes, a result consistent with
biological intolerance. Based on this result, we reasoned that a
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Figure 4. Celf6-like immunoreactivity in serotonergic nuclei. A, Celf6 immunoblot of whole-cell lysates from 3T3 fibroblasts transfected with a long isoform of Celf6, a short isoform of Celf6, or
a short isoform of Celf6 fused to GFP demonstrates specificity of antibody to target. B, GFP and Celf6 immunofluorescence in 3T3 fibroblasts transfected with Celf6-GFP (as in A). C, Celf6
immunofluorescence in Slc6a4 bacTRAP mice demonstrates colocalization of Celf6 with eGFP-L10a in serotonergic neurons of dorsal raphe.

focused resequencing effort, enabling deep characterization of
key functional regions, should be used.
Toward this end, we selected three regions for our first screen of
CELF6. This included the area around the alternative first exon 1b,
where the common variant was identified, as well as the exon 12,
which contains a short CAG repeat (Fig. 3B). Finally, we also targeted
the exon 11 because available EST data suggest that it is used exclusively by humans: no other available species show any mRNA or
ESTs aligning to it (Fig. 3B). Of course, as human, mouse, and rat
sequences dominate the EST databases, these data could represent a
loss of the exon in rodents, rather than a gain in humans.
Thus, we sequenced the promoter and alternative first exon
1b, as well as exons 11–13 in 384 male white probands (randomly
selected from previous AGRE probands) and 384 normal male
white controls (new samples). In this semi-independent sample,
we found no common alleles showing stronger association than
rs2959930 (Fisher’s exact test, p ⬍ 0.051), although one novel
low-frequency intronic variant was seen only in controls (Table 3,
p ⬍ 0.0012). We did not detect any instances of triplet repeat
expansion in exon 12, although extraordinarily large repeats
would not be assayable with PCR-based methods.
We did, however, discover a premature stop codon in one
autistic patient (Fig. 5A) and no controls. This SNP is found in
the putative human-specific exon 11 and would be predicted
to lead nonsense-mediated decay, and thus is likely a loss of
function allele. No coding sequence variations were identified
in the 384 controls. The presence of this rare variant in an

autistic patient provides further evidence implicating this
gene in autism, although it clearly cannot account for the
original transmission disequilibrium findings. Sequencing of
the entire pedigree (AU1397) reveals that the variant was inherited from the father, suggesting incomplete penetrance if
the allele is involved in autism. There is also additional strong
matrilineal contribution for autism in this family, as the proband has affected twin siblings and matrilineal cousins not
harboring this allele (Fig. 5B). Although not included in the
AGRE consortium, the father’s extended family also included
additional individuals with intellectual disability and reportedly odd behavior.
To determine whether this rare variant is found in any additional cases or controls, we designed both a primer-extension
(Sequenom) assay as well as an allele-specific PCR (Fig. 5C, D).
Analysis of 4992 normal individuals, as well as 864 autistic individuals from the Simons Simplex Collection, identified no additional cases or controls harboring this allele, highlighting the
rarity of the variant. Likewise, this variant was not seen in the
1092 individuals above, or the ⬃5000 individuals currently available in the Exome Variant Server (http://evs.gs.washington.edu/
EVS/)[3/2012].
Like other cases of extremely rare variants detected in autism,
such as many of the exonic deletions (Bucan et al., 2009) and
other copy number variants (Pinto et al., 2010), it is difficult to
amass sufficient power to draw statistical conclusions regarding
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Table 3. Results of Celf6 resequencing study

DBsnp

Amplicon

Position
within
amplicon

Novel
Novel
Novel
Novel
Novel
Novel
Novel
Novel
Novel
Novel
Novel
rs4625684
rs2959930
rs2959930
Novel
rs74026061
Novel
Novel
rs2959928
rs2959929
Novel
Novel
Novel

B1
B1
B1
B1
B2
B2
B2
B2
B2
B2
B2
A3
A3
A3
A3
A3
A3
A3
A4
A4
A4
A4
A4

129
150
247
263
88
104
200
362
391
459
513
60
147
147
151
165
166
234
91
159
233
50
169

SNP

AGRE, % (no.) of samples
with SNP detected, of
interpretable reads

Controls, % (no.) of samples
with SNP detected, of
interpretable reads

p value (Fisher’s test),
deviating from
expected (Controls)

Type

Confirmed

C 3 CG
C 3 CG
T 3 CT
T 3 CT
C 3 CG
T 3 TC
G 3 AG
G 3 GA
T 3 CT
G 3 AG
C 3 CT
T3C
C 3 CT
C3T
C 3 CT
G 3 CG
C 3 CT
C 3 CT
C 3 CT
G 3 AG
C 3 CT
G 3 AG
C 3 AC

0.27% (1/370)
0.27% (1/370)
0.81% (3/370)
0.27% (1/370)
0.53% (2/375)
0% (0/375)
0.28% (1/357)
0% (0/375)
0% (0/375)
0% (0/375)
0% (0/375)
100% (282/282)
29.43% (83/282)
6.74% (19/282)
0.71% (2/282)
0.35% (1/282)
0% (0/282)
0.35% (1/282)
1.06% (4/377)
4.26% (16/376)
0.27% (1/376)
0% (0/376)
0% (0/376)

0% (0/355)
0% (0/355)
0.57% (2/353)
0.57% (2/353)
0.29% (1/341)
0.29% (1/341)
0% (0/341)
0.29% (1/341)
0.29% (1/341)
2.64% (9/341)
0.29% (1/341)
100% (357/357)
35.85% (128/357)
3.64% (13/357)
1.12% (4/357)
0% (0/357)
0.28% (1/357)
0% (0/357)
0% (0/363)
2.48% (9/363)
0% (0/363)
0.28% (1/363)
0.28% (1/363)

0.510
0.510
0.522
0.469
0.536
0.476
0.511
0.476
0.476
0.001
0.476
1.000
0.051
0.055
0.459
0.441
0.559
0.441
0.067
0.129
0.509
0.491
0.491

Stop
Intron
Intron
Intron
Intron
Intron
Intron
Intron
Intron
Intron
Intron
Promoter/intron
5⬘ UTR
5⬘ UTR
5⬘ UTR
5⬘ UTR
5⬘ UTR
5⬘ UTR
Promoter/intron
Promoter/intron
Promoter/intron
Promoter/intron
Promoter/intron

Yesa
None
None
None
None
None
None
None
None
None
None
In dbSNP
In dbSNP
In dbSNP
None
In dbSNP
None
None
In dbSNP
In dbSNP
None
None
None

a

Confirmed in proband and father with bidirectional Sanger sequencing, as well as sequenome and allele-specific PCR assays.
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Figure 5. PrematurestopcodoninCELF6inafamilywithautism.A,NovelcodingSNPidentifiedinhuman-specificexon.Toprow,Proband303showsC-⬎C/G.Bottomrow,NormalDNA.Translationshown
beneath each. Red arrow indicates heterozygote Y-⬎stop SNP. B, Pedigree of Family AU1397. **Not sequenced. *Has stop Y-⬎ Stop. C, Example of quantitative RT-PCR melt curves from 96 allele specific
PCRs. 95 amplified only ␤-actin (genomic control). Positive control DNA (proband 303) amplified both ␤-actin and mutant Celf6 allele. D, Summary of all assays for mutant Celf6 allele.

the relevance of such an extremely rare variant. Also, similar to
what is seen in deletions of NRXN1 and 16p11, this polymorphism, if contributing to causation, is not showing complete penetrance in the afflicted family (Abrahams and Geschwind, 2010).

Further statistical validation of this allele now awaits more
complete resequencing studies of CELF6, a byproduct of ongoing
large-scale autism exome sequencing efforts. However, even with
these studies, the human genetics alone will still likely be under-
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Figure 6. Celf6 mutant mice show loss of Celf6 signal in brain, and Celf6 ⫺/⫺ mouse pups show deficits in early communicative behaviors. A, Immunofluorescent confocal microscopy of dorsal
raphe neurons, labeled with GFP antibody (green), reveals loss of Celf6 antibody staining (red) in Celf6 ⫺/⫺ mice. B, Celf6 ⫺/⫺ mouse pups produce significantly fewer ultrasonic syllables per 3 min
recording session compared with WT mice (ANOVA, *p ⫽ 0.001). Data are mean ⫾ SEM.

powered. In addition, reanalysis of published microarray datafrom human lymphoblasts reveals that CELF6 is not detectable in
these cells (Luo et al., 2012), precluding any straightforward
patient-based allelic expression imbalance analyses. Therefore,
we decided to investigate this allele functionally by creating a
mutation in mouse and testing for autism-like behaviors.
Characterization of Celf6 mutant mice
Autism is characterized by abnormal social interactions and language delay, as well as restricted interests and resistance to
change. To determine whether mutations in Celf6 could contribute to analogous abnormalities in mouse behavior, we deleted the
constitutive fourth exon of Celf6. This deletion introduces premature stop codons in all known isoforms of Celf6 and, like the
human mutation, would be predicted to result in nonsensemediated decay of mRNA. PCR confirmed the deletion of the
locus in the genome. Quantitative RT-PCR from mouse brain
confirmed decrease of Celf6 mRNA (data not shown). Examination of the brain using nuclear stains (DAPI) and neuronal staining (NeuN) did not reveal any gross morphological differences.
However, immunofluorescence using Celf6 antibodies confirms
a loss of Celf6 signal from cells in all regions of the brain, including raphe neurons (Fig. 6A). Behavioral studies were then conducted to characterize Celf6 ⫺/⫺ and littermate WT control mice
during both development and later in adulthood. It was our goal

not only to study behaviors that may be related to autism but also
to broadly characterize the phenotype of Celf6 ⫺/⫺ mice also, as
this is the first report of deletion in mice.
Celf6ⴚ/ⴚ pups have decreased ultrasonic vocalizations
To determine whether Celf6 ⫺/⫺ mice exhibited any alterations in
communication-related behaviors during early development, we
conducted the standard maternal isolation test, which is frequently used to evaluate mouse models of autism (Hofer et al.,
2002; Chadman et al., 2008; Scattoni et al., 2008; Nakatani et al.,
2009). Eight-day-old mouse pups exhibit robust stereotyped vocalizations in the ultrasonic range when separated from their
dam. These calls (“syllables”) (Holy and Guo, 2005) can be considered a form of social communication as they elicit a retrieval
response from the dam. Celf6 ⫺/⫺ pups produced 60% fewer syllables per 3 min recording session compared with WT littermates
(Fig. 6B, ANOVA; F(1,42) ⫽ 12.794, p ⫽ 0.001). The significant
reduction in vocalization in Celf6 ⫺/⫺ pups was further observed
between genotypes within each sex separately (F(1,42) ⫽ 5.792,
p ⫽ 0.02 for females, F(1,42) ⫽ 7.049, p ⫽ 0.01 for males; not
shown) with no significant difference between sexes. There was
no difference in body weights between groups, suggesting that the
vocalization effect was not the result of gross developmental delay
(data not shown). Results from this assay can be interpreted as
reflecting alterations in anxiety levels or communicative function
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significantly (25%) faster than the WT
70
control group (Fig. 7D; rmANOVA– ge60
notype effect: F(1,18) ⫽ 8.13, p ⫽ 0.011).
50
Importantly, no differences were ob40
served between groups with regard to spa30
tial learning and memory; no effects
20
involving genotype were found for path
10
length (Fig. 7E) or latency (not shown)
0
4
12
20
during the place (hidden platform) trials,
PPI TRIALS
and no retention performance deficits
(db ABOVE BACKGROUND)
were evident during the probe trial in
7. Adult male Celf6 ⫺/⫺ mice demonstrate intact sensorimotor and spatial learning functions. A, B, Adult male
terms of spatial bias (Fig. 7F ), platform Figure
⫺/⫺
and WT mice performed similarly on several basic behavioral assays. A, Comparable levels of general ambulatory activity
crossings, or time in the target quadrant Celf6
⫺/⫺
and WT mice during the 1 h locomotor activity test. B, Celf6 ⫺/⫺ mice did not exhibit any performance
(data not shown). The increased swim- were observed in Celf6
(data not shown). C–F, The Celf6 ⫺/⫺
ming speeds in the Celf6 ⫺/⫺ mice during deficits on the ledge test or on any of the other 6 measures within the sensorimotor battery
mice also generally performed at control-like levels on the Morris water maze. C, Celf6 ⫺/⫺ and WT controls exhibited comparable
the cued trials were a transitory effect bepath lengths to the escape platform during cued trials, indicating that the Celf6 ⫺/⫺ mice did not display nonassociative dysfunccause no differences were observed be- tions that would interfere with subsequent learning and memory performance in the water maze. D, Celf6 ⫺/⫺ mice swam
tween groups on this variable during the significantly faster than the WT controls during the cued trials in the water maze (rmANOVA– genotype effect, ††p ⫽ 0.011,
place (spatial learning) trials. Sensorimo- pairwise comparisons: **p ⫽ 0.004 and *p ⫽ 0.012). E, WT and Celf6 ⫺/⫺ groups performed equally well during the place trials
tor reactivity and gating were also evalu- in the water maze, suggesting that spatial learning was not impaired. F, During the probe trial, both the Celf6 ⫺/⫺ and WT mice
ated in the mice, but no significant effects spent more time in the target (TGT) quadrant where the platform had previously been (rmANOVA with planned comparisons, *p ⬍
involving genotype were found for either 0.003 and †p ⬍ 0.025, respectively) compared with the right (RGT), opposite (OPP), and left (LFT) quadrants, suggesting that
the acoustic startle response (data not retention was not impaired. G, Equivalent levels of PPI were observed in the two groups of mice, indicating normal sensorimotor
shown) or PPI (Fig. 7G). In summary, the gating and startle responses. Data are mean ⫾ SEM.
above results suggest that Celf6 ⫺/⫺ mice
The mice were also evaluated on standard social interaction
did not have demonstrable deficits in nonassociative (visual, senassays involving the social approach test (Moy et al., 2004;
sorimotor, or motivational) functions and that their spatial
Silverman et al., 2011), the results of which showed that the
learning and memory appeared to be intact, at least for reference
Celf6 ⫺/⫺ mice performed like WT controls. In the first social
memory-based capabilities.
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100
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showed high levels of anxiety-like behaviors in the EPM because it might have relevance to interpreting the vocalization
results. Specifically, the Celf6 ⫺/⫺ mice exhibited control-like levels in terms of time
spent (Fig. 8C), distance traveled (Fig.
8D), and entries made into the open arms,
as well as the percentages of these variables computed with reference to totals
observed in both sets of arms (not
shown). Thus, analyzing the classic variables thought to represent anxiety-like behaviors in the EPM did not reveal any
differences between the Celf6 ⫺/⫺ and WT
control mice. These results suggest that
the USV deficit was not likely the result of
any consistent lifelong differences in anxiety but instead may reflect an impairment
in early social communication.

Celf6ⴚ/ⴚ mice show evidence of
resistance to change
TEST DAYS
TEST DAYS
Another diagnostic criterion of autism inFigure 8. Adult Celf6 ⫺/⫺ mice exhibit control-like levels of sociability, social preference, and anxiety-like behaviors. A, During volves resistance to change. Although
⫺/⫺
mice exhibited intact spatial
the first social approach test, adult Celf6 ⫺/⫺ and WT mice both showed normal sociability preference for a novel stimulus mouse Celf6
over an empty withholding cage during the test trial (rmANOVA with planned comparisons, *p ⬍ 0.00004). B, During the second learning and retention during in the Morsocial approach test, adult Celf6 ⫺/⫺ mice spent more time investigating the cagemate compared with the empty withholding ris water maze, they swam faster than the
cage during test trial 1 (**p ⬍ 0.005), demonstrating no deficits in sociability toward a familiar cagemate. During test trial 2, adult WT control group when introduced into
Celf6 ⫺/⫺ and WT mice both displayed a preference for social novelty by spending more time investigating the novel stimulus the pool during the cued trials, an effect
mouse compared with a familiar cagemate during test trial 2 (rmANOVA with planned comparisons, *p ⬍ 0.0003). C, D, Adult
that disappeared with extended exposure
Celf6 ⫺/⫺ and WT mice showed similar levels of anxiety-like behaviors as indexed by the amount of time spent (C) and distance
during the place trials. This initial increase
traveled (D) in the open arms of the elevated plus maze. Data are mean ⫾ SEM.
in swimming speeds in the Celf6 ⫺/⫺ mice
⫺/⫺
approach test sequence, neither Celf6
suggests an altered response in these mice to a significant change
nor WT control mice
demonstrated investigation zone biases during the habituation
in environmental conditions. To evaluate the mice more formally
trial (empty vs target zone, Fig. 8A), presenting no confounding
for resistance to change, we evaluated their performance during
issues for the interpretation of the test trial results. We assessed
reversal trials in the water maze. In the first block of trials, the
sociability exhibited toward a novel stimulus mouse versus an
Celf6 ⫺/⫺ mice exhibited a tendency toward considerably longer
escape latencies and path lengths (Fig. 9A, B), although planned
empty withholding cage during the test trial, and rmANOVAs
comparisons showed that these differences were not significantly
conducted on the relevant variables did not reveal significant
different (F(1,18) ⫽ 3.88, p ⫽ 0.065 and F(1,18) ⫽ 3.45, p ⫽ 0.080,
effects involving genotype. More importantly, planned comparrespectively). Consistent with the data from the place trials, the
isons conducted within each group showed that both groups
groups performed in a similar manner in the later blocks of trials,
spent significantly more time investigating a novel stimulus
with regard to swimming speeds, and during the probe trial (data
mouse compared with an empty withholding cage, whether meanot shown).
sured by time in the investigation zone surrounding the cage (Fig. 8A;
Based on the differences observed during the first block of
F(1,18) ⫽ 37.30, p ⫽ 0.000009 for Celf6 ⫺/⫺, F(1,18) ⫽ 43.45, p ⫽ 0.000003
for WT), or by time spent in the chamber (F(1,18) ⫽ 17.30, p ⫽
reversal trials, we decided that a less stressful behavioral task,
0.0006 for Celf6 ⫺/⫺, F(1,18) ⫽ 25.75, p ⫽ 0.0008 for WT not
which involved exploratory behavior using the primary sensory
shown). A second social approach test conducted at a slightly
system of mice (olfaction), might provide a more sensitive test of
later age involved quantifying social preference for a same-sex
the resistance-to-change phenotype. A type of holeboard task has
cagemate versus a novel stimulus mouse. Again, neither Celf6 ⫺/⫺
been used to study behaviors in mice considered to be analogous
nor WT control mice demonstrated investigation zone biases
to the resistance to change and restricted interests found in peoduring the habituation trial (empty vs target zone, Fig. 8B). The
ple with autism-spectrum disorder (Moy et al., 2008; Silverman
Celf6 ⫺/⫺ mice showed no deficits in sociability toward a cageet al., 2011). Our modified version of this holeboard test
mate during test trial 1. No differences were found between
(Ghoshal et al., 2012) was used to evaluate both exploratory and
Celf6 ⫺/⫺ and WT control mice during test trial 2 in that both
olfactory preference behaviors and whether familiarization with
groups of mice spent significantly more time in the investigation
the putative reward value of an odorant could alter behavior.
zone (Fig. 8B; F(1,16) ⫽ 30.46, p ⫽ 0.00005 for Celf6 ⫺/⫺, F(1,16) ⫽
Figure 9C shows a schematic of the holeboard apparatus as well as
23.51, p ⫽ 0.0002 for WT) and chamber (F(1,16) ⫽ 12.59, p ⫽
the placement of odorants into the corner holes for test sessions 1
0.003 for Celf6 ⫺/⫺, F(1,16) ⫽ 9.28, p ⫽ 0.008 for WT) containing
and 2. The results from ANOVAs showed that, initially, Celf6 ⫺/⫺
a novel stimulus mouse compared with the times spent in the
and WT mice displayed similar general hole-poke frequencies
same areas where a cagemate was contained.
with regard to total and corner hole-pokes (Fig. 9D, E, left), as
Given the robust decreases in USV observed in the Celf6 ⫺/⫺
well as side (empty) hole-pokes (not shown). Within-subjects
mouse pups, we were interested to determine whether they
comparisons revealed that both groups also poked significantly
0
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more often (F(1,18) ⫽ 17.83, p ⫽ 0.0005 for
Celf6 ⫺/⫺, F(1,18) ⫽ 8.58, p ⫽ 0.009 for WT)
into the hole containing a familiar odorant (fresh homecage bedding) than the
empty corner hole (Fig. 9F, left), suggesting
that both Celf6 ⫺/⫺ and WT mice have intact
olfactory abilities, and a baseline preference
for familiar bedding, as do other strains of
mice (Moy et al., 2008). Poke frequencies
did not differ between groups for any odorant or the empty corner hole at baseline.
After test session 1, the mice were familiarized with the chocolate chips by
permitting consumption over a two-day
period before they were tested on the
holeboard again, with the odorants being
placed in the corner holes as depicted in
Figure 9C (right, test session 2). Familiarization with the chocolate chips had a profound effect on exploratory hole-poking
and olfactory preference behaviors in the
WT control mice but had no effect on the
Celf6 ⫺/⫺ group. For example, the results
of ANOVAs showed that, after familiarization, WT mice made significantly
greater numbers of total hole-pokes (Fig.
9D, F(1,18) ⫽ 12.46, p ⫽ 0.002), corner
hole-pokes (Fig. 9E, F(1,18) ⫽ 16.71, p ⫽
0.0007), and side hole-pokes (F(1,18) ⫽ 6.185,
p ⫽ 0.023; data not shown) compared with
the Celf6 ⫺/⫺ group. Most importantly,
familiarization with the chocolate also
had a major impact on differences in poke
frequencies into the odorant-containing
and empty corner holes (Fig. 9F, right).
For example, a significant genotype by
hole interaction (F(3,54) ⫽ 2.814, p ⫽
0.048) for test session 2, followed by subsequent comparisons showed that the WT
mice poked significantly more often into
the holes containing the novel bedding
(F(1,18) ⫽ 9.90, p ⫽ 0.006), and particularly the chocolate chips (F(1,18) ⫽ 15.91,
p ⫽ 0.0009), compared with the Celf6 ⫺/⫺
group, with large differences also observed between groups in hole-pokes into
the hole containing familiar bedding
(F(1,18) ⫽ 6.51, p ⫽ 0.020, Bonferronicorrected critical p ⫽ 0.013). Moreover,
within-subjects comparisons revealed that the
Celf6 ⫺/⫺ mice showed no preference for
any odorant over the empty corner hole
during test session 2, whereas the WT
group showed significant preferences
(F(3,16) ⫽ 14.13, p ⫽ 0.00009), for the familiar bedding ( p ⫽ 0.0002), novel bedding ( p ⫽ 0.006), and chocolate ( p ⫽
0.00005) over the empty corner hole
(Bonferroni corrected critical p ⫽ 0.017).
Thus, familiarization with the chocolate
had a robust effect on WT control mice in
terms of increasing their general exploratory hole poking and changing their ol-
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Figure 9. Adult Celf6 ⫺/⫺ mice showed evidence of resistance to change. A, B, There were no significant performance differences between groups during the reversal trials in the water maze, although there were nonsignificant trends for the Celf6 ⫺/⫺
mice to have longer escape latencies (A, rmANOVA with pairwise comparisons, p ⫽ 0.065) and path lengths (B, rmANOVA with
pairwise comparisons, p ⫽ 0.080) compared with the WT group. C–F, Holeboard assay for resistance to change. C, A schematic of
the holeboard showing the location of odorants and empty holes for test session 1 and test session 2 (after familiarization with
chocolate). D, Celf6 ⫺/⫺ and WT mice showed equivalent exploratory behavior (hole-poke frequencies) during test session 1.
Celf6 ⫺/⫺ mice failed to show the potentiation of exploratory behavior after familiarization with chocolate that was exhibited
by the WT controls in terms of total hole-pokes (ANOVA, p ⫽ 0.002). E, The increase in exploratory behavior by WT mice
occurred largely in the corner holes (ANOVA, p ⫽ 0.0007). F, Before familiarization, Celf6 ⫺/⫺ and WT mice showed
equivalent exploratory behavior as both groups showed preference for holes containing familiar bedding compared with
the empty corner holes (rmANOVA with planned comparisons, *p ⬍ 0.010), suggesting normal olfactory capacities for both
groups (test session 1). After familiarization, WT mice poked significantly more often than the Celf6 ⫺/⫺ mice into the
holes containing novel bedding (rmANOVA with planned comparisons, p ⫽ 0.006) and, particularly, chocolate chips ( p ⫽
0.0009), with large differences into the hole containing familiar bedding ( p ⫽ .020). Overall, the WT group also showed
significant preferences for the holes containing odorants over the empty corner hole (*p ⬍ 0.007), whereas the Celf6 ⫺/⫺
mice failed to show any change in exploratory hole poking or evidence of olfactory preferences following familiarization to
the chocolate. Data are mean ⫾ SEM.
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tions of monoaminergic systems, we used
mass spectrometry to measure total levels
of three monoamines in the brains of
Celf6 ⫺/⫺ and WT mice. We observed a
30 ⫾ 4% (mean ⫾ SEM) decrease in serotonin levels ( p ⬍ 0.002, Bonferroni corrected), and similar trends in
norepinephrine and dopamine ( p ⬍ 0.08,
⬍ 0.04, respectively, before Bonferroni
corrections, not significant after) in brains
of Celf6 ⫺/⫺ mice (Fig. 10). There was no
effect on levels of the GABA, glycine, or
glutamate (not shown) neurotransmitters
( p ⬎ 0.88, p ⬎ 0.23, and p ⬎ 0.28, respectively, no Bonferroni correction), demonstrating the specificity of the effect to
neurons previously seen to be expressing
Celf6.

Discussion

The paradigms of the previous era of human genetics, typified by observations of a
suspicious looking variant in a few famiWT mean
0.47 **
9.08
0.42
60.34
10.35
lies and nothing similar in a few hundred
families, are insufficient to cope with the
WT s.d.
0.05
0.73
0.1
7.36
0.76
overwhelming catalogs of variants being
discovered now (Neale et al., 2012;
-/10.36
0.37 **
8.52
0.35
57.36
Celf6 mean
O’Roak et al., 2012; Sanders et al., 2012).
Results like those reported here are be-/1.44
0.05
0.73
0.03
4.64
Celf6 s.d.
coming standard: an inherited variant
within a compelling candidate gene is obFigure 10. Celf6 ⫺/⫺ mice show decreased brain serotonin levels. LC-MS/MS measures of levels of neuromodulatory neu- served only once in thousands of families.
rotransmitters serotonin (5HT), norepinephrine (NE), and dopamine (DA) reveal a significant decrease (**p ⬍ 0.002) in 5HT levels, This highlights the need not only to inand nonsignificant trend for NE and DA in whole brains from n ⬎ 7 WT and Celf6 ⫺/⫺ mice. There is no change in the negative crease our sample sizes, but also to find
control transmitters GABA and glycine. Data are plotted as a percentage of WT ion count levels; error bars represent SEM. Tables new analytical approaches to this comprovide absolute levels in pMol.
plexity to overcome issues of power. We
propose here that a broader adoption of
blended strategies, drawing simultanefactory preferences, whereas the Celf6 ⫺/⫺ group showed a
ously
on
statistical
genetics
and empirical biology, are required.
resistance to change on either of these two behavioral dimensions
There is a growing consensus that many psychiatric disorders
after exposure to the chocolate.
are strongly influenced by a diverse set of rare, nearly private
We also measured duration of hole-pokes to determine
mutations (McClellan and King, 2010; Pinto et al., 2010). Thus, it
whether it was likely that the Celf6 ⫺/⫺ and WT groups were
is likely that there are multiple genetic routes to developing a
processing the olfactory stimuli in a different manner. Our analparticular disorder, or even individual symptoms within a disoryses showed that there were no differences between the groups
der. Yet these diverse genetic routes must converge at some
with regard to the durations of total hole-pokes or for pokes
smaller number of common pathways in their molecular or celmade into odorant-containing or empty holes for either test seslular neurobiology to engender a common behavioral phenotype.
sion (data not shown). These findings along with the similar
Therefore, we have combined a unique and unbiased method for
hole-poking performances of the groups before familiarization
generating key biological priors in mice, with analysis of genetic
with the chocolate provide evidence that the groups did not differ
variation in humans, and functional validation in murine modin their abilities to discriminate odors. Rather, our holeboard
els, to identify a gene contributing to some of the essential diagresults suggest that mutations in CELF6 may contribute aunostic features of autism. We propose that this kind of paradigm,
tism risk by influencing the propensity to modify behavior in
leveraging information at multiple analytical levels, may be reresponse to a rewarding experience. More generally, our required to dissect complex genetic disorders. By working from the
sults provide evidence that Celf6 contributes to a subset of the
hypotheses that serotonergic abnormalities may contribute to a
autism-like behaviors that were assayed in the present study.
reasonable fraction of the cases of autism, we were able to reduce
the penalties taken by looking at common variation genomeCelf6ⴚ/ⴚ mice have abnormal levels of CNS serotonin
wide, as well as appropriately direct our functional assays in mice.
Finally, our initial bacTRAP screen was to identify genes that may
More broadly, although the evidence linking serotonergic neube important for the regulation of the serotonergic system in the
rons to some cases of autism is alluring, the true extent of the
brain (Figs. 1, 2), and we determined that Celf6 protein in mice
contribution of this cell type remains to be established. Several
was indeed found fairly specifically in monoamine-containing
lines of evidence suggest that a subset of cases of autism may
neurons within the brainstem (Fig. 4). To determine whether the
changes in behavior seen might indeed be the result of perturbainvolve a perturbation of the serotonergic system. Multiple studpmol
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ies have detected abnormally high levels of serotonin in whole
blood of a subset (⬎25%) of autistic patients (Schain and
Freedman, 1961; Takahashi et al., 1976; Anderson et al., 1987;
Cook, 1990). A combination of genetic investigation, neural imaging, and drug treatment have all implicated corresponding dysregulation of serotonin-related genes and pathways in affected
individuals (McDougle et al., 1996b, 1997; McDougle et al., 1998;
Chugani et al., 1999; Chandana et al., 2005; Coon et al., 2005;
Hollander et al., 2005). For example, selective serotonin reuptake
inhibitors have been shown to alleviate rigid/compulsive behaviors in some cases (Gordon et al., 1993; McDougle et al., 1996b;
Hollander et al., 2011) and depletion of serotonin in autistic individuals exacerbates these symptoms (McDougle et al., 1996a).
Likewise, genetic or pharmacological perturbation of the serotonergic system in rodents alters behavioral responses which characterize animal models of autism, such as altered USV, repetitive
behavior, social interaction, and resistance to change (Olivier et
al., 1998; Fish et al., 2000; Lopez-Rubalcava et al., 2000;
Whitaker-Azmitia, 2001; McNamara et al., 2008; Nakatani et al.,
2009). Most recently, Veenstra-VanderWeele et al. (2012) have
shown that introduction of an autism-associated human coding
variant in the serotonin transporter gene into mice resulted in a
number of autism-related behaviors, such as impaired USV, decreased social dominance, and increased repetitive behaviors.
Our behavioral results suggest that, although Celf6 ⫺/⫺ and
WT mice performed similarly on several different tests, the
Celf6 ⫺/⫺ mice exhibited certain selective functional deficits that
may be analogous to the behavioral impairments that exist in a
subset of people with autism. Specifically, Celf6 ⫺/⫺ and WT mice
performed similarly on several behavioral assays, including: a 1-h
locomotor activity test; a battery of sensorimotor measures; spatial learning and memory performance in the Morris water maze;
various tests of social interaction as indexed by the social approach test; and anxiety-like behaviors quantified in the elevated
plus maze. However, reduction of isolation-induced USV suggests that Celf6 ⫺/⫺ pups show early communication deficits. The
measurement of USV in response to maternal isolation is an established assay that has been used in several other mouse models
of autism, including the BTBR, Shank1 null, and neuroligin models (Chadman et al., 2008; Scattoni et al., 2008; Nakatani et al.,
2009). Although genotypic differences in pup USV may be the
result of either communication deficits or changes to anxiety, we
feel the latter is unlikely as adult Celf6 ⫺/⫺ mice did not exhibit
differences compared with littermate WT control mice in
anxiety-like behaviors measured during elevated plus maze testing. However, we acknowledge that it will be important to evaluate vocalization in Celf6 ⫺/⫺ mice at later stages, such as during
juvenile play and adult mating, and this is one of our future
research aims. Our behavioral data also suggest that Celf6 ⫺/⫺
mice react abnormally to certain environmental alterations and
may be resistant to changing their behavior under conditions that
robustly alter WT mouse behavior. For example, Celf6 ⫺/⫺ swam
faster than controls when first introduced into the water maze
during cued trials, but this effect habituated and was not present
during the place condition. Also, familiarizing the mice with
chocolate chips during the holeboard exploration/olfactory preference test led to robust changes in the behavioral responses of
the WT control group, whereas Celf6 ⫺/⫺ mice showed a resistance to such changes. Specifically, familiarization with the chocolate in WT mice led to greatly increased exploratory hole poking
and distinct olfactory preferences for several odorants, whereas
Celf6 ⫺/⫺ showed no such changes. These results are similar to
those reported by Moy et al., 2008 who used a slightly different

procedure to show that BTBR mice exhibit a similar resistance to
change after familiarization with chocolate. Our holeboard results provide evidence that mutations in CELF6 may promote
autism risk by modifying behavioral responses to rewarding experiences. However, it will be necessary to further characterize
the resistance to change in olfactory preference in Celf6 ⫺/⫺ mice
after exposure to various rewarding odorant stimuli, and we are
conducting additional studies to this end. Our initial behavioral
data suggest that Celf6 ⫺/⫺ mice exhibit selective deficits and may
serve as a model for understanding a subset of autism-like
behaviors.
Still, additional mechanistic studies are needed to inform both
the Celf6 and the serotonergic contribution to autism in general.
Although Celf6 is clearly enriched in these cells, and serotonin is
decreased in the brains of Celf6 ⫺/⫺ mice, conditional deletion
and rescue studies are needed to confirm the behavioral abnormalities are cell-autonomous to the serotonergic system. Likewise, although we have provided evidence for this gene at
multiple levels (a common 5⬘UTR variant and a rare heterozygous stop codon in humans, and homozygous deletions in
mouse), each of these levels warrants additional investigation to
generate a comprehensive view of the contribution of this gene.
Although the common variant is linked with autism in the AGRE
sample, this finding does not replicate in the Simons Simplex
Collection (J. K. Lowe, personal communication), although that
sample was smaller and optimized for finding idiopathic and
especially de novo events rather than inherited, familial causes.
The most parsimonious interpretation of our CELF6 findings
thus far is that CELF6 levels may influence some behaviors relevant to autism; thus, there are alleles in this gene that contribute
to risk of developing autism in a subset of patients. This would be
consistent with autism being a highly heterogeneous and polygenic disorder; there are likely to be many genes with this type and
magnitude of effect. This may also explain the incomplete penetrance seen in the family with the CELF6 mutation: resistance to
change, in the absence of social deficits, would be insufficient to
generate a diagnosis for autism. This would be consistent with
recent studies, which suggest that the restricted interests and sociability components are factorially separable and partially genetically independent (Happe and Ronald, 2008; Frazier et al., 2012;
Robinson et al., 2012). Thus, other genes and cell types likely
contribute more to the social symptoms. An unbiased screen
using this same approach systematically across many cell types
may permit inferences regarding circuitry important to the neurobiology of autism.
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Heiman M, Schaefer A, Gong S, Peterson JD, Day M, Ramsey KE, SuárezFarinas M, Schwarz C, Stephan DA, Surmeier DJ, Greengard P, Heintz N
(2008) A translational profiling approach for the molecular characterization of CNS cell types. Cell 135:738 –748. CrossRef Medline
Hillarp NA, Fuxe K, Dahlström A (1966) Demonstration and mapping of
central neurons containing dopamine, noradrenaline, and 5-hydroxytryptamine and their reactions to psychopharmaca. Pharmacol Rev 18:
727–741. Medline
Hofer MA, Shair HN, Brunelli SA (2002) Ultrasonic vocalizations in rat and
mouse pups. Curr Protoc Neurosci Chapter 8:Unit 8.14. CrossRef
Medline
Hollander E, Phillips A, Chaplin W, Zagursky K, Novotny S, Wasserman S,
Iyengar R (2005) A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology 30:582–589. CrossRef Medline
Hollander E, Soorya L, Chaplin W, Anagnostou E, Taylor BP, Ferretti CJ,
Wasserman S, Swanson E, Settipani C (2012) A double-blind placebocontrolled trial of fluoxetine for repetitive behaviors and global severity in

2752 • J. Neurosci., February 13, 2013 • 33(7):2732–2753
adult autism spectrum disorders. Am J Psychiatry 169:292–299 CrossRef
Medline
Holy TE, Guo Z (2005) Ultrasonic songs of male mice. PLoS Biol 3:e386.
CrossRef Medline
Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, Qi Y, Scherer SW,
Lee C (2004) Detection of large-scale variation in the human genome.
Nat Genet 36:949 –951. CrossRef Medline
Ishimura K, Takeuchi Y, Fujiwara K, Tominaga M, Yoshioka H, Sawada T
(1988) Quantitative analysis of the distribution of serotoninimmunoreactive cell bodies in the mouse brain. Neurosci Lett 91:265–
270. CrossRef Medline
Kessler RC, McGonagle KA, Swartz M, Blazer DG, Nelson CB (1993) Sex
and depression in the National Comorbidity Survey: I. Lifetime prevalence, chronicity and recurrence. J Affect Disord 29:85–96. CrossRef
Medline
Korte SM, Meijer OC, de Kloet ER, Buwalda B, Keijser J, Sluyter F, van
Oortmerssen G, Bohus B (1996) Enhanced 5-HT1A receptor expression
in forebrain regions of aggressive house mice. Brain Res 736:338 –343.
CrossRef Medline
Ladd AN, Nguyen NH, Malhotra K, Cooper TA (2004) CELF6, a member of
the CELF family of RNA-binding proteins, regulates muscle-specific
splicing enhancer-dependent alternative splicing. J Biol Chem 279:
17756 –17764. CrossRef Medline
Lein ES, Hawrylycz MJ, Ao N, Ayres M, Bensinger A, Bernard A, Boe AF,
Boguski MS, Brockway KS, Byrnes EJ, Chen L, Chen L, Chen TM, Chin
MC, Chong J, Crook BE, Czaplinska A, Dang CN, Datta S, Dee NR, et al
(2007) Genome-wide atlas of gene expression in the adult mouse brain.
Nature 445:168 –176. CrossRef Medline
Little S (2001) Amplification-refractory mutation system (ARMS) analysis
of point mutations. In: Current Protocols in Human Genetics. New York:
Wiley.
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